Felbamate

Anti-epileptic Agent — NERVOUS SYSTEM

Key facts

Felbamate is an ofp drug in the Anti-epileptic Agent class catalogued in DrugCentral. It was first approved by the FDA in 1993. DrugCentral lists 2 molecular targets, including GRIN2B and GRIN2A. Recorded indications include Epilepsy, Lennox-Gastaut syndrome and Simple partial seizure.

• Approval status: ofp (first approved 1993 by the FDA).
• Drug class: Anti-epileptic Agent.
• Molecular targets: GRIN2B and GRIN2A (2 listed in DrugCentral).
• Indications: Epilepsy, Lennox-Gastaut syndrome and Simple partial seizure.
• ATC code: N03AX10 (Other antiepileptics).
• Molecular formula: C11H14N2O4; molecular weight 238.24 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Epilepsy
• Lennox-Gastaut syndrome
• Simple partial seizure

Contraindications (14)

• Aplastic anemia
• Bone marrow depression
• Breastfeeding (mother)
• Congenital long QT syndrome
• Depressive disorder
• Disease of blood AND/OR blood-forming organ
• Disease of liver
• Hepatic failure
• Kidney disease
• Liver function tests abnormal
• Porphyria
• Prolonged QT interval
• Suicidal thoughts
• Torsades de pointes

Mechanism & targets

• Established pharmacologic class: Anti-epileptic Agent

Molecular targets (2)

Target	Gene	Action	Activity
Glutamate receptor ionotropic, NMDA 2B	GRIN2B	antagonist	IC50 4.28
Glutamate receptor ionotropic, NMDA 2A	GRIN2A	antagonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1993-07-29	FDA	—	MEDA PHARMS	Yes

ATC classification

ATC code	Therapeutic hierarchy
N03AX10	NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Other antiepileptics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Seizure	669.5
Multiple-drug resistance	151.5
Generalised tonic-clonic seizure	141.9
Drug ineffective	127.7
Somnolence	81.6
Petit mal epilepsy	78.0
Laryngeal stenosis	62.7
Unmasking of previously unidentified disease	61.6
Toxicity to various agents	60.2
Electrocardiogram repolarisation abnormality	58.7
Benzodiazepine drug level decreased	56.5
Electrocardiogram ST segment elevation	53.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Felbamate is on its molecule page.

• Molecular formula: C₁₁H₁₄N₂O₄
• Molecular weight: 238.24 g/mol
• CAS number: 25451-15-4
• InChIKey: WKGXYQFOCVYPAC-UHFFFAOYSA-N
• PubChem CID: 3331

NC(=O)OCC(COC(N)=O)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Felbamate used for?

DrugCentral lists the following indications for Felbamate: Epilepsy, Lennox-Gastaut syndrome and Simple partial seizure.

How does Felbamate work?

Its molecular targets in DrugCentral include GRIN2B (antagonist) and GRIN2A (antagonist).

When was Felbamate first approved?

Felbamate was first approved by the FDA in 1993.

What drug class does Felbamate belong to?

Felbamate is in the Anti-epileptic Agent class.

What is the chemical formula of Felbamate?

Felbamate has the molecular formula C11H14N2O4 and a molecular weight of 238.24 g/mol.

Sources

• DrugCentral drug card 1140 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1094 — compound record and bioactivity
• PubChem CID 3331 — chemical identifiers
• DrugBank DB00949 — drug record
• FDA UNII X72RBB02N8 — substance identity
• DailyMed: FDA labels for Felbamate — current prescribing information (label search)
• UniProt Q13224 (GRIN2B) — target protein
• UniProt Q12879 (GRIN2A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.